General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview


  • Bradyrhizobium neotropicale is a Gram-negative, non-spore-forming, aerobic, motile, rod-shaped bacterium. It has been detected in at least 1 gut microbiome compilation study or metastudy. The DNA G+C content is 63.9%. Bradyrhizobium neotropicale is probably a rare gut coloniser. (Zilli2014)



  • This organism has been recovered from human faeces and root nodules. Pathogenicity status unknown, or very unlikely to be pathogenic. A possible gut commensal.

  • GENERAL CHARACTERISTICS (Zilli2014);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; urea;
  • 🧂
  • Salt tolerance:
  • tolerates 1% salt;
  • pH
  • Acidity tolerance:
  • tolerates pH 4.0; tolerates pH 10; Grows optimally at pH 5.0-7.0.
  • 🌡
  • Temperature tolerance:
  • grows at 15℃; grows at 37℃; Grows optimally at 28-32℃.
  • Substrates assimilated or utilised:
  • L-arabinose; d_arabitol; fructose; fucose; galactose; gluconate; glycerol; mannitol; mannose; rhamnose; D-alanine; aspartate; glutamate; leucine; phenylalanine; acetate; citrate; formate; 3-hydroxybutyrate; 2-ketoglutarate; DL-lactate; malonate; quinate; saccharate; sebacate; succinate; glutamine; L-asparagine; α-ketobutyrate; 2-hydroxybutyrate; 4-hydroxybutyrate; methyl succinate; succinamate; methyl pyruvate; p-hydroxyphenylacetate;
  • Active enzymes:
  • arginine dihydrolase; catalase; oxidase; urease;

  • SPECIAL FEATURES
    Character Response
  • Nitrate:
  • not reduced

  • RESPONSE TO ANTIBIOTICS (Zilli2014);
    Class Active Resistant
  • Penicillins:
  • penicillin;
  • Macrolides:
  • erythromycin;
  • Aminoglycosides:
  • streptomycin;

  • Details


    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Alphaproteobacteria Order:  Hyphomicrobiales Family:  Bradyrhizobiaceae Genus:  Bradyrhizobium Gram stain:  neg O2 Relation.:  aerobic Spore:  No spore Motility:  Swimming Morphology:  Rod
    Health:  Unknown
    Source:  human faeces and root nodules
    DNA G+C(%):  63.9
    Opt. T:  28-32℃
    Low T(℃):  15(+)
    Mid T(℃):  37(+)
    NaCl 0.5-2%:  1(+)
    Opt. pH:  5.0-7.0
    pH 4.2-5.9:  4.0(+)
    pH >8:  10(+)
    Aesculin:  + Urea:  + Gelatin:  neg

    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Glucose:  neg

    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    L-Arabinose:  + Fructose:  + Fucose:  + Galactose:  + Mannose:  + Rhamnose:  + Cellubiose:  neg N_Acetyl_glucosamine:  neg Adonitol:  neg D-Arabitol:  + Gluconate:  + Glycerol:  + Mannitol:  + D-Ala:  + 4-Aminobutyrate:  neg Asp:  + Glu:  + Leu:  + Phe:  + Pro:  neg Thr:  neg Acetate:  + Citrate:  + Formate:  + 3-Hydroxybutyrate:  + DL-Lactate:  + Malonate:  + Quinate:  + Saccharate:  + Sebacate:  + Succinate:  +

    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  + Catalase:  + Urease:  + β-Galactosidase:  neg ArgDH:  + TrpAA:  neg

    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    penicillin:  S(10; disc)
    gentamicin:  Var(MIC50): 10; disc), MIC90: Var(10; disc
    streptomycin:  S(10; disc)
    erythromycin:  R(30; disc)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)

    References


    SPECIFIC REFERENCES FOR BRADYRHIZOBIUM NEOTROPICALE
  • Zilli2014 - Bradyrhizobium neotropicale sp. nov., isolated from effective nodules of Centrolobium paraense.
  • ...............................
  • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR BRADYRHIZOBIUM NEOTROPICALE
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • ...............................